The functional assessment of cancer therapy scale: Development and validation of the general measure

David F. Cella, David S. Tulsky, George Gray, Bernie Sarafian, Elizabeth Linn, Amy Bonomi, Margaret Silberman, Suzanne B. Yellen, Patsy Winicour, Judy Brannon, Karen Eckberg, Stephen Lloyd, Sandy Purl, Carol Blendowski, Michelle Goodman, Madeline Barnicle, Irene Stewart, Marnie McHale, Philip Bonomi, Edward KaplanSamuel Taylor IV, Charles Thomas, Jules Harris

Research output: Contribution to journalArticle

3548 Citations (Scopus)

Abstract

Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. Methods and Results: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. Conclusion: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.

Original languageEnglish (US)
Pages (from-to)570-579
Number of pages10
JournalJournal of Clinical Oncology
Volume11
Issue number3
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Quality of Life
Reproducibility of Results
Clinical Trials
Aptitude
Statistical Factor Analysis
Colorectal Neoplasms
Lung Neoplasms
Hospitalization
Interviews
Breast Neoplasms
Weights and Measures

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., ... Harris, J. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579. https://doi.org/10.1200/JCO.1993.11.3.570

The functional assessment of cancer therapy scale : Development and validation of the general measure. / Cella, David F.; Tulsky, David S.; Gray, George; Sarafian, Bernie; Linn, Elizabeth; Bonomi, Amy; Silberman, Margaret; Yellen, Suzanne B.; Winicour, Patsy; Brannon, Judy; Eckberg, Karen; Lloyd, Stephen; Purl, Sandy; Blendowski, Carol; Goodman, Michelle; Barnicle, Madeline; Stewart, Irene; McHale, Marnie; Bonomi, Philip; Kaplan, Edward; Taylor IV, Samuel; Thomas, Charles; Harris, Jules.

In: Journal of Clinical Oncology, Vol. 11, No. 3, 01.01.1993, p. 570-579.

Research output: Contribution to journalArticle

Cella, DF, Tulsky, DS, Gray, G, Sarafian, B, Linn, E, Bonomi, A, Silberman, M, Yellen, SB, Winicour, P, Brannon, J, Eckberg, K, Lloyd, S, Purl, S, Blendowski, C, Goodman, M, Barnicle, M, Stewart, I, McHale, M, Bonomi, P, Kaplan, E, Taylor IV, S, Thomas, C & Harris, J 1993, 'The functional assessment of cancer therapy scale: Development and validation of the general measure', Journal of Clinical Oncology, vol. 11, no. 3, pp. 570-579. https://doi.org/10.1200/JCO.1993.11.3.570
Cella, David F. ; Tulsky, David S. ; Gray, George ; Sarafian, Bernie ; Linn, Elizabeth ; Bonomi, Amy ; Silberman, Margaret ; Yellen, Suzanne B. ; Winicour, Patsy ; Brannon, Judy ; Eckberg, Karen ; Lloyd, Stephen ; Purl, Sandy ; Blendowski, Carol ; Goodman, Michelle ; Barnicle, Madeline ; Stewart, Irene ; McHale, Marnie ; Bonomi, Philip ; Kaplan, Edward ; Taylor IV, Samuel ; Thomas, Charles ; Harris, Jules. / The functional assessment of cancer therapy scale : Development and validation of the general measure. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 3. pp. 570-579.
@article{86f3130c74aa40c59772500b20d6b4b6,
title = "The functional assessment of cancer therapy scale: Development and validation of the general measure",
abstract = "Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. Methods and Results: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. Conclusion: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.",
author = "Cella, {David F.} and Tulsky, {David S.} and George Gray and Bernie Sarafian and Elizabeth Linn and Amy Bonomi and Margaret Silberman and Yellen, {Suzanne B.} and Patsy Winicour and Judy Brannon and Karen Eckberg and Stephen Lloyd and Sandy Purl and Carol Blendowski and Michelle Goodman and Madeline Barnicle and Irene Stewart and Marnie McHale and Philip Bonomi and Edward Kaplan and {Taylor IV}, Samuel and Charles Thomas and Jules Harris",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.3.570",
language = "English (US)",
volume = "11",
pages = "570--579",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - The functional assessment of cancer therapy scale

T2 - Development and validation of the general measure

AU - Cella, David F.

AU - Tulsky, David S.

AU - Gray, George

AU - Sarafian, Bernie

AU - Linn, Elizabeth

AU - Bonomi, Amy

AU - Silberman, Margaret

AU - Yellen, Suzanne B.

AU - Winicour, Patsy

AU - Brannon, Judy

AU - Eckberg, Karen

AU - Lloyd, Stephen

AU - Purl, Sandy

AU - Blendowski, Carol

AU - Goodman, Michelle

AU - Barnicle, Madeline

AU - Stewart, Irene

AU - McHale, Marnie

AU - Bonomi, Philip

AU - Kaplan, Edward

AU - Taylor IV, Samuel

AU - Thomas, Charles

AU - Harris, Jules

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. Methods and Results: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. Conclusion: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.

AB - Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. Methods and Results: The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. Conclusion: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.

UR - http://www.scopus.com/inward/record.url?scp=0027407786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027407786&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.3.570

DO - 10.1200/JCO.1993.11.3.570

M3 - Article

C2 - 8445433

AN - SCOPUS:0027407786

VL - 11

SP - 570

EP - 579

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -